Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study
Primary Purpose
Heart Disease
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
EPA-DHA Study
Sponsored by

About this trial
This is an interventional prevention trial for Heart Disease
Eligibility Criteria
Inclusion Criteria:
- Healthy male or surgically sterile females between ages 21-70.
- Body Mass Index of 20-35.
- Plasma Lipoprotein Associated Phospholipase A2 (LpPLA2) values > 200 ng/ml.
Exclusion Criteria:
- Competitive exerciser.
- Current smoker.
- Those already taking dietary supplements (EPA, DHA, flax seed oil, fish oil, cod liver oil, weight control products, or high doses of vitamin C (>500 mg/day) or vitamin E (>400 mg/day).
- Those consuming more than 3 oily fish species/week.
- Those consuming >2 drinks containing alcohol/day.
- Those taking medications which could affect serum lipids or body weight, or taking coumadin or more than 325 mg/day of aspirin which could effect bleeding time or the coagulation profile.
- History of a bleeding disorder.
- History of significant cardiac, renal, hepatic, gastro-intestinal, pulmonary, neoplastic, biliary or endocrine disorders including uncontrolled diabetes, thyroid disease, or hypertension.
- Plasma LpPLA2 values < 200 ng/ml.
Sites / Locations
- Cardiovascular Research Associates
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Placebo Comparator
Active Comparator
Active Comparator
Active Comparator
Arm Label
Olive Oil 6 grams/day
DHA 1800 mg/day
EPA 1800 mg/day
Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day
Arm Description
Outcomes
Primary Outcome Measures
plasma EPA levels as well as the EPA/DHA ratio and plasma DHA levels as well as the DHA/EPA ratio
Subjects receiving EPA at 1800 mg/day will have significantly greater plasma EPA levels as well as the EPA/DHA ratio than the placebo group or the group receiving DHA, while the group receiving DHA will have significantly greater increases in plasma DHA levels as well as the DHA/EPA ratio than the placebo group or the group receiving EPA.
Secondary Outcome Measures
LpPLA2
Subjects receiving the active supplement, especially at the 1800 mg daily dose of EPA will have significant reductions in LpPLA2 as compared to both baseline values and to the placebo group.
Full Information
NCT ID
NCT01400490
First Posted
July 21, 2011
Last Updated
July 21, 2011
Sponsor
Cardiovascular Research Associates
Collaborators
Dupont Applied Biosciences
1. Study Identification
Unique Protocol Identification Number
NCT01400490
Brief Title
Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study
Official Title
Evaluation of the Biologic Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)-Enriched Oils (EPA-DHA Study)
Study Type
Interventional
2. Study Status
Record Verification Date
July 2011
Overall Recruitment Status
Unknown status
Study Start Date
September 2010 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
September 2011 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Cardiovascular Research Associates
Collaborators
Dupont Applied Biosciences
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The goal of the study is to test the efficacy of an EPA-enriched oil made by DuPont versus a DHA-enriched oil, a standard fish oil preparation, and olive oil placebo in a double-blind, randomized, placebo-controlled trial. This study will compare the efficacy of 1800 mg/day of EPA versus 1800 mg/day of DHA versus a fish oil product containing 1800 mg of EPA and 1200 mg of DHA/day as compared to olive oil placebo at 6 grams/day over a 6 week period in a parallel arm design study of 120 healthy adults studied in both the fasting and post-prandial state. Safety will be monitored by assessing for adverse reactions, measuring vital signs and a variety of lab tests including a complete metabolic profile and complete blood count. Efficacy will be assessed by measuring changes in fatty acid profile and or fatty acid ratios,as well as by measuring plasma lipids, lipoproteins, and markers of inflammation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Disease
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Olive Oil 6 grams/day
Arm Type
Placebo Comparator
Arm Title
DHA 1800 mg/day
Arm Type
Active Comparator
Arm Title
EPA 1800 mg/day
Arm Type
Active Comparator
Arm Title
Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day
Arm Type
Active Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
EPA-DHA Study
Intervention Description
6 weeks of dietary supplementation
Primary Outcome Measure Information:
Title
plasma EPA levels as well as the EPA/DHA ratio and plasma DHA levels as well as the DHA/EPA ratio
Description
Subjects receiving EPA at 1800 mg/day will have significantly greater plasma EPA levels as well as the EPA/DHA ratio than the placebo group or the group receiving DHA, while the group receiving DHA will have significantly greater increases in plasma DHA levels as well as the DHA/EPA ratio than the placebo group or the group receiving EPA.
Time Frame
Six weeks
Secondary Outcome Measure Information:
Title
LpPLA2
Description
Subjects receiving the active supplement, especially at the 1800 mg daily dose of EPA will have significant reductions in LpPLA2 as compared to both baseline values and to the placebo group.
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy male or surgically sterile females between ages 21-70.
Body Mass Index of 20-35.
Plasma Lipoprotein Associated Phospholipase A2 (LpPLA2) values > 200 ng/ml.
Exclusion Criteria:
Competitive exerciser.
Current smoker.
Those already taking dietary supplements (EPA, DHA, flax seed oil, fish oil, cod liver oil, weight control products, or high doses of vitamin C (>500 mg/day) or vitamin E (>400 mg/day).
Those consuming more than 3 oily fish species/week.
Those consuming >2 drinks containing alcohol/day.
Those taking medications which could affect serum lipids or body weight, or taking coumadin or more than 325 mg/day of aspirin which could effect bleeding time or the coagulation profile.
History of a bleeding disorder.
History of significant cardiac, renal, hepatic, gastro-intestinal, pulmonary, neoplastic, biliary or endocrine disorders including uncontrolled diabetes, thyroid disease, or hypertension.
Plasma LpPLA2 values < 200 ng/ml.
Facility Information:
Facility Name
Cardiovascular Research Associates
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02112
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
26074314
Citation
Tsunoda F, Lamon-Fava S, Asztalos BF, Iyer LK, Richardson K, Schaefer EJ. Effects of oral eicosapentaenoic acid versus docosahexaenoic acid on human peripheral blood mononuclear cell gene expression. Atherosclerosis. 2015 Aug;241(2):400-8. doi: 10.1016/j.atherosclerosis.2015.05.015. Epub 2015 May 19.
Results Reference
derived
Learn more about this trial
Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study
We'll reach out to this number within 24 hrs